Quantum Biopharma adds March release to registration

Quantum Biopharma files a technical 6-K amendment to link a prior press release into its Form F-3 registration statement, with no other changes disclosed.

Rhea-AI Filing Summary

Quantum Biopharma Ltd. (QNTM) furnishes Amendment No. 1 to a previously submitted Form 6-K from March 30, 2026. The amendment’s sole purpose is to have Exhibit 99.1, a press release dated March 30, 2026, formally incorporated by reference into the company’s Registration Statement on Form F-3 (File No. 333-276264).

The company states there are no other changes to the original Form 6-K beyond this incorporation-by-reference step.

Key Terms

foreign private issuer, Form F-3, incorporated by reference

3 terms

foreign private issuer regulatory

"FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form F-3 regulatory

"incorporated by reference into the Registrant’s Registration Statement on Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

incorporated by reference regulatory

"is hereby incorporated by reference into the Registrant’s Registration Statement"

FAQ

What is Quantum Biopharma Ltd. (QNTM) changing with this Form 6-K/A?

The amendment makes Exhibit 99.1, a press release dated March 30, 2026, part of Quantum Biopharma’s Form F-3 Registration Statement (File No. 333-276264) by incorporation by reference. The company states there are no other changes to the original March 30, 2026 Form 6-K.

Does this 6-K/A for QNTM modify any financial results or guidance?

No. The amendment specifies that, except for incorporating Exhibit 99.1 into the Form F-3, there are no other changes to the initial March 30, 2026 Form 6-K. It does not present or revise financial results or guidance.

Which exhibit is being incorporated by reference for Quantum Biopharma (QNTM)?

The filing incorporates by reference Exhibit 99.1, described as a Press Release dated March 30, 2026, into Quantum Biopharma’s Registration Statement on Form F-3 (File No. 333-276264).

From what date is Exhibit 99.1 deemed part of QNTM’s Form F-3?

Exhibit 99.1 is deemed part of the Form F-3 from the date on which the initial Form 6-K was furnished, March 30, 2026, to the extent not superseded by documents or reports subsequently filed or furnished.

Who signed this Form 6-K/A for Quantum Biopharma Ltd. (QNTM)?

The amendment was signed on behalf of Quantum Biopharma Ltd. by Donal Carroll, who is identified as the company’s Chief Financial Officer, dated September 8, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 12:39 PM Accepted by SEC EDGAR 09/08/2026 - 12:38 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number:  001-39152

QUANTUM BIOPHARMA LTD.

(Registrant)

1 Adelaide Street East, Suite 801

Toronto, Ontario M5C 2V9

(Address of Principal Executive Offices) 

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

EXPLANATORY NOTE

This Amendment No. 1 (this “Amendment No. 1”) to the report on Form 6-K originally furnished with the U.S. Securities and Exchange Commission on March 30, 2026, Accession Number 0001171843-26-002008 (the “Initial Report”), is being furnished solely to incorporate Exhibit 99.1 filed as part of the Initial Report into the Registrant’s Registration Statement on Form F-3 (File No. 333-276264). Except as set forth herein, there are no other changes to the Initial Report.

1

DOCUMENTS INCORPORATED BY REFERENCE

Exhibit 99.1 included with this Amendment No. 1 is hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 (File No. 333-276264) and shall be deemed to be a part thereof from the date on which the Initial Report was furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	QUANTUM BIOPHARMA LTD.
	(Registrant)
Date: September 8, 2026	By	/s/ Donal Carroll
		Donal Carroll
		Chief Financial Officer

3

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Press Release dated March 30, 2026 (incorporated by reference to Exhibit 99.1 to the Form 6-K furnished on March 30, 2026, Accession No. 0001171843-26-002008)

4